Our Pricing

BMI For Wegovy: Get Your Online Prescription in 3 Minutes

Understanding your BMI for Wegovy online prescription UK eligibility is the first step towards effective weight management. At Cured Pharmacy, our UK-registered prescribers assess your BMI and medical history in under 3 minutes, providing transparent pricing from £79.00 and discreet next-day delivery across the UK.

What BMI Do You Need for Wegovy in the UK?

Wegovy (semaglutide) is licensed by the MHRA for adults with a BMI of 30 kg/m² or above, or a BMI of 27 kg/m² or above with at least one weight-related health condition such as type 2 diabetes, hypertension, or obstructive sleep apnoea [1]. These criteria align with NICE guidance on prescribing GLP-1 receptor agonists for weight management in the UK.

Your BMI is calculated by dividing your weight in kilograms by your height in metres squared. For example, a person weighing 90kg and measuring 1.75m tall has a BMI of 29.4 kg/m². Our online assessment includes an automatic BMI calculator, and our UK prescribers review your individual circumstances to determine suitability.

It's important to note that BMI is just one factor. Our clinical team, led by superintendent pharmacist Tarun Kumar (GPhC 2233073), also considers your medical history, current medications, and weight loss goals to ensure Wegovy is the safest and most appropriate option for you.

How Wegovy Works for Weight Loss

Wegovy contains semaglutide, a GLP-1 (glucagon-like peptide-1) receptor agonist that mimics a natural hormone your body produces after eating [2]. This medication works through three primary mechanisms: it slows gastric emptying to help you feel fuller for longer, reduces appetite signals in the brain, and improves blood sugar regulation.

In the landmark STEP 1 clinical trial, patients using Wegovy achieved an average weight reduction of 14.9% of their initial body weight over 68 weeks, compared to 2.4% with placebo [2]. Participants also reported improvements in cardiovascular risk factors including blood pressure, cholesterol levels, and waist circumference.

Wegovy is administered as a once-weekly subcutaneous injection, starting at a low dose of 0.25mg and gradually increasing over 16-20 weeks to the maintenance dose of 2.4mg. This dose escalation schedule, determined through extensive clinical research, minimises gastrointestinal side effects whilst optimising weight loss outcomes.

Expected Results and Timeline

Most patients begin noticing reduced appetite within the first 2-4 weeks of treatment, with measurable weight loss typically evident by week 8-12 [2]. The STEP trials demonstrated that maximal weight loss generally occurs between 60-68 weeks of continuous treatment, though individual responses vary based on adherence, lifestyle modifications, and metabolic factors.

Your 3-Minute Online Prescription Process

At Cured Pharmacy, we've streamlined the prescription process to take under 3 minutes whilst maintaining rigorous clinical standards. You'll complete a confidential medical questionnaire covering your weight history, current health conditions, medications, and lifestyle factors. Our UK-registered prescribers review every assessment individually—there are no automated approvals.

If Wegovy is deemed clinically appropriate, your prescription is issued electronically and sent directly to our UK-licensed dispensary. We provide transparent upfront pricing at £79.00 before you complete the consultation, with no hidden fees or subscription charges. Your medication is dispensed in 100% discreet packaging and dispatched via next-day courier.

Should Wegovy not be suitable based on your BMI or medical history, our prescribers may recommend alternative treatments or suggest consulting your GP for additional support. This ensures you receive genuinely personalised care rather than a one-size-fits-all approach.

What Happens After Approval

Once approved, you'll receive detailed injection instructions, a sharps disposal container, and access to our clinical support team. We recommend follow-up consultations every 4-8 weeks to monitor progress, adjust dosing if needed, and address any side effects. All follow-up assessments are included at no additional cost.

Wegovy Pricing and Value at Cured Pharmacy

Wegovy is available at Cured Pharmacy from £79.00, representing competitive UK pricing with our lowest price guarantee. This includes your medication, free clinical consultation, next-day discreet delivery, and ongoing prescriber support. Unlike some services, we display all costs before you begin the assessment—no surprises at checkout.

The cost reflects the current UK supply situation and MHRA-licensed product availability. Each Wegovy pen contains four pre-filled doses, and your monthly requirement depends on your current dose level in the titration schedule. Our prescribers will clearly explain your treatment duration and associated costs during the consultation.

We accept all major payment methods and never require subscription commitments. You can order monthly supplies as needed, pause treatment if required, or switch to alternative medications based on your evolving clinical needs and budget.

Managing Side Effects and Safety Considerations

The most common side effects of Wegovy are gastrointestinal in nature, including nausea, diarrhoea, vomiting, and constipation [3]. These symptoms typically occur during dose escalation and diminish as your body adapts to the medication. In clinical trials, approximately 44% of patients reported nausea, though severe cases leading to discontinuation were rare at around 4% [3].

To minimise side effects, our prescribers recommend eating smaller, more frequent meals, avoiding high-fat foods, and staying well-hydrated. Taking your injection on the same day each week and at a consistent time can also help your body establish a routine. If side effects persist beyond 2-3 weeks at a given dose, your prescriber may adjust the titration schedule.

Wegovy is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 [4]. It should be used with caution in those with a history of pancreatitis, severe gastrointestinal disease, or diabetic retinopathy. Our clinical assessment specifically screens for these conditions to ensure your safety.

When to Contact Your Prescriber

Seek immediate medical attention if you experience severe abdominal pain that doesn't resolve, persistent vomiting preventing fluid intake, vision changes, or signs of allergic reaction. Our clinical team is available via phone on (+44) 116 4646009 during business hours, and we provide emergency guidance for after-hours concerns.

Lifestyle Support and Long-Term Success

Wegovy is most effective when combined with a reduced-calorie diet and increased physical activity [2]. Clinical trials required participants to receive nutritional counselling and aim for at least 150 minutes of moderate exercise weekly—factors that contributed significantly to the 14.9% average weight loss observed.

We recommend working with a registered dietitian or nutritionist to develop sustainable eating patterns that complement your medication. Focus on whole foods, adequate protein intake (1.2-1.6g per kg of ideal body weight), and fibre-rich vegetables to support satiety whilst meeting nutritional needs during weight loss.

Long-term success also requires addressing behavioural and psychological factors. Many patients benefit from support groups, cognitive behavioural therapy for eating behaviours, or apps that track food intake and activity. Our prescribers can provide referrals to appropriate services and monitor your holistic progress beyond just the number on the scale.

Importantly, weight maintenance after stopping Wegovy requires continued lifestyle modifications. The STEP 4 trial showed that patients who discontinued semaglutide regained approximately two-thirds of their lost weight within one year [5]. Discussing a long-term maintenance strategy with your prescriber before stopping treatment is essential for sustained results.

Scientific References

1. National Institute for Health and Care Excellence. (2023). Semaglutide for managing overweight and obesity [TA875]. NICE.
2. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
3. Novo Nordisk. (2023). Wegovy 2.4 mg solution for injection in pre-filled pen: Summary of Product Characteristics. Electronic Medicines Compendium.
4. Medicines and Healthcare products Regulatory Agency. (2023). Wegovy (semaglutide): conditions of use, contraindications, and warnings. GOV.UK.
5. Rubino, D., Abrahamsson, N., Davies, M., et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Wegovy is a prescription-only medicine and suitability is determined on an individual basis following review of your medical history and current health status.